Pier Luigi Meroni

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4020902/publications.pdf

Version: 2024-02-01

541 papers	38,873 citations	3930 88 h-index	4427 172 g-index
572 all docs	572 docs citations	572 times ranked	22418 citing authors

#	Article	IF	Citations
1	International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). Journal of Thrombosis and Haemostasis, 2006, 4, 295-306.	1.9	6,039
2	Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis and Rheumatism, 2002, 46, 1019-1027.	6.7	1,736
3	2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2019, 71, 1400-1412.	2.9	1,098
4	2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2019, 78, 1151-1159.	0.5	759
5	EULAR recommendations for the management of antiphospholipid syndrome in adults. Annals of the Rheumatic Diseases, 2019, 78, 1296-1304.	0.5	664
6	Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Annals of the Rheumatic Diseases, 2015, 74, 1011-1018.	0.5	610
7	EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Annals of the Rheumatic Diseases, 2017, 76, 476-485.	0.5	590
8	Accelerated Atherosclerosis in Autoimmune Rheumatic Diseases. Circulation, 2005, 112, 3337-3347.	1.6	484
9	Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nature Reviews Rheumatology, 2011, 7, 330-339.	3.5	482
10	International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Annals of the Rheumatic Diseases, 2014, 73, 17-23.	0.5	471
11	Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Research and Therapy, 2006, 8, 209.	1.6	469
12	Risk of congenital complete heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis: A prospective study of 100 women. Arthritis and Rheumatism, 2001, 44, 1832-1835.	6.7	435
13	ANA screening: an old test with new recommendations. Annals of the Rheumatic Diseases, 2010, 69, 1420-1422.	0.5	425
14	Thrombus formation induced by antibodies to Î²2-glycoprotein I is complement dependent and requires a priming factor. Blood, 2005, 106, 2340-2346.	0.6	324
15	Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. Blood, 2003, 101, 3495-3500.	0.6	290
16	Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. Annals of the Rheumatic Diseases, 2009, 68, 1428-1432.	0.5	262
17	Statins prevent endothelial cell activation induced by antiphospholipid (anti-?2-glycoprotein I) antibodies: Effect on the proadhesive and proinflammatory phenotype. Arthritis and Rheumatism, 2001, 44, 2870-2878.	6.7	250
18	Cardiovascular disease in autoimmune rheumatic diseases. Autoimmunity Reviews, 2013, 12, 1004-1015.	2.5	232

#	Article	IF	Citations
19	14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends. Autoimmunity Reviews, 2014, 13, 917-930.	2.5	224
20	Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a. European Journal of Endocrinology, 1995, 132, 587-593.	1.9	218
21	Complement activation in patients with COVID-19: AÂnovel therapeutic target. Journal of Allergy and Clinical Immunology, 2020, 146, 215-217.	1.5	210
22	Antiphospholipid Antibodies and the Antiphospholipid Syndrome: Pathogenic Mechanisms. Seminars in Thrombosis and Hemostasis, 2008, 34, 236-250.	1.5	205
23	Infectious origin of the antiphospholipid syndrome. Annals of the Rheumatic Diseases, 2006, 65, 2-6.	0.5	203
24	Pediatric Antiphospholipid Syndrome: Clinical and Immunologic Features of 121 Patients in an International Registry. Pediatrics, 2008, 122, e1100-e1107.	1.0	193
25	Expression of cytokines, chemokines and other effector molecules in two prototypic autoinflammatory skin diseases, pyoderma gangrenosum and Sweet's syndrome. Clinical and Experimental Immunology, 2014, 178, 48-56.	1.1	191
26	Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. Autoimmunity Reviews, 2011, 10, 444-454.	2.5	186
27	Toll-like receptor and antiphospholipid mediated thrombosis: in vivo studies. Annals of the Rheumatic Diseases, 2007, 66, 1327-1333.	0.5	184
28	X Chromosome Monosomy: A Common Mechanism for Autoimmune Diseases. Journal of Immunology, 2005, 175, 575-578.	0.4	180
29	Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study. Annals of the Rheumatic Diseases, 2011, 70, 1083-1086.	0.5	178
30	Protection against inflammation- and autoantibody-caused fetal loss by the chemokine decoy receptor D6. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 2319-2324.	3.3	171
31	Updating on the pathogenesis of systemic lupus erythematosus. Autoimmunity Reviews, 2010, 10, 3-7.	2.5	170
32	Anti-C1q antibodies may help in diagnosing a renal flare in lupus nephritis. American Journal of Kidney Diseases, 2001, 37, 490-498.	2.1	168
33	Anti-beta 2-glycoprotein I antibodies: a marker of antiphospholipid syndrome?. Lupus, 1995, 4, 122-130.	0.8	165
34	International consensus guidelines on anticardiolipin and antiâ€“Î²₂â€glycoprotein I testing: Report from the 13th International Congress on Antiphospholipid Antibodies. Arthritis and Rheumatism, 2012, 64, 1-10.	6.7	163
35	TH1 and TH2 cytokine production by peripheral blood mononuclear cells from HIV-infected patients. Aids, 1994, 8, 757-762.	1.0	159
36	The geoepidemiology of the antiphospholipid antibody syndrome. Autoimmunity Reviews, 2010, 9, A299-A304.	2.5	159

#	Article	IF	Citations
37	Differential Effects of Antiâ€“Î²2-Glycoprotein I Antibodies on Endothelial Cells and on the Manifestations of Experimental Antiphospholipid Syndrome. Circulation, 1998, 97, 900-906.	1.6	150
38	Autoantibodies against nuclear pore complexes are associated with more active and severe liver disease in primary biliary cirrhosis. Journal of Hepatology, 2001, 34, 366-372.	1.8	150
39	Autoimmunity and Anti-TNF-Î± Agents. Annals of the New York Academy of Sciences, 2005, 1051, 559-569.	1.8	150
40	Current Concepts and Future Directions for the Assessment of Autoantibodies to Cellular Antigens Referred to as Anti-Nuclear Antibodies. Journal of Immunology Research, 2014, 2014, 1-18.	0.9	148
41	Pregnancy outcome in 100 women with autoimmune diseases and anti-Ro/SSA antibodies: a prospective controlled study. Lupus, 2002, 11, 716-721.	0.8	140
42	Endothelial Activation by aPL: A Potential Pathogenetic Mechanism for the Clinical Manifestations of the Syndrome. Journal of Autoimmunity, 2000, 15, 237-240.	3.0	139
43	Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis. American Journal of Kidney Diseases, 2004, 43, 28-36.	2.1	139
44	Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model. Arthritis and Rheumatism, 2003, 48, 3272-3279.	6.7	138
45	Minimal requirements for antiphospholipid antibodies ELISAs proposed by the European Forum on antiphospholipid antibodies. Thrombosis Research, 2004, 114, 553-558.	0.8	138
46	Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis. Arthritis and Rheumatism, 2002, 46, 1602-1613.	6.7	137
47	Anti-Phospholipid Antibodies in COVID-19 Are Different From Those Detectable in the Anti-Phospholipid Syndrome. Frontiers in Immunology, 2020, 11, 584241.	2.2	137
48	Brief Report: Successful pregnancies but a higher risk of preterm births in patients with systemic sclerosis: An Italian multicenter study. Arthritis and Rheumatism, 2012, 64, 1970-1977.	6.7	134
49	Anti-endothelial cell IgG antibodies from patients with Wegener's granulomatosis bind to human endothelial cells in vitro and induce adhesion molecule expression and cytokine secretion. Arthritis and Rheumatism, 1996, 39, 758-766.	6.7	132
50	Impaired serum cholesterol efflux capacity in rheumatoid arthritis and systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2014, 73, 609-615.	0.5	132
51	European consensus statement on the terminology used in the management of lupus glomerulonephritis. Lupus, 2009, 18, 257-263.	0.8	131
52	Pyoderma gangrenosum and its syndromic forms: evidence for a link with autoinflammation. British Journal of Dermatology, 2016, 175, 882-891.	1.4	131
53	Complement activation and endothelial perturbation parallel COVID-19 severity and activity. Journal of Autoimmunity, 2021, 116, 102560.	3.0	127
54	Vitamin D: an instrumental factor in the anti-phospholipid syndrome by inhibition of tissue factor expression. Annals of the Rheumatic Diseases, 2011, 70, 145-150.	0.5	126

#	Article	IF	Citations
55	Sex and Management of Rheumatoid Arthritis. Clinical Reviews in Allergy and Immunology, 2019, 56, 333-345.	2.9	126
56	â€˜Criteriaâ€™ aPL tests: Report of a Task Force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, Texas, April 2010. Lupus, 2011, 20, 182-190.	0.8	122
57	Autoinflammatory Skin Disorders in Inflammatory Bowel Diseases, Pyoderma Gangrenosum and Sweetâ€™s Syndrome: a Comprehensive Review and Disease Classification Criteria. Clinical Reviews in Allergy and Immunology, 2013, 45, 202-210.	2.9	122
58	Fluvastatin inhibits up-regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells. Journal of Thrombosis and Haemostasis, 2004, 2, 1558-1563.	1.9	121
59	Treatment of pregnant patients with antiphospholipid syndrome. Lupus, 2003, 12, 524-529.	0.8	120
60	A nonâ€“complement-fixing antibody to Î²2 glycoprotein I as a novel therapy for antiphospholipid syndrome. Blood, 2014, 123, 3478-3487.	0.6	120
61	The Long-Term Prognosis of Renal Transplantation in Patients With Lupus Nephritis. American Journal of Kidney Diseases, 2005, 45, 903-911.	2.1	119
62	IL-18 cDNA vaccination protects mice from spontaneous lupus-like autoimmune disease. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 14181-14186.	3.3	118
63	Primary biliary cirrhosis and SjÃ¶grenâ€™s syndrome: Autoimmune epithelitis. Journal of Autoimmunity, 2012, 39, 34-42.	3.0	118
64	Classification of anti-endothelial cell antibodies into antibodies against microvascular and macrovascular endothelial cells: The pathogenic and diagnostic implications. Arthritis and Rheumatism, 2001, 44, 1484-1494.	6.7	114
65	In vivo distribution of Î²2 glycoprotein I under various pathophysiologic conditions. Blood, 2011, 118, 4231-4238.	0.6	113
66	Pregnancy and reproduction in autoimmune rheumatic diseases. Rheumatology, 2011, 50, 657-664.	0.9	112
67	Association of Pyoderma Gangrenosum, Acne, and Suppurative Hidradenitis (PASH) Shares Genetic and Cytokine Profiles With Other Autoinflammatory Diseases. Medicine (United States), 2014, 93, e187.	0.4	108
68	The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 1000 consecutive cases. Autoimmunity Reviews, 2019, 18, 406-414.	2.5	106
69	QT interval prolongation in asymptomatic anti-SSA/Roâ€“positive infants without congenital heart block. Arthritis and Rheumatism, 2000, 43, 1049.	6.7	105
70	Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study. Arthritis Research and Therapy, 2006, 8, R3.	1.6	105
71	Endothelium and the brain in CNS lupus. Lupus, 2003, 12, 919-928.	0.8	102
72	Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: Effects of tumor necrosis factor-Î± blockade. Journal of Autoimmunity, 2008, 31, 175-179.	3.0	102

#	Article	IF	Citations
73	Treatment strategies and pregnancy outcomes in antiphospholipid syndrome patients with thrombosis and triple antiphospholipid positivity. Thrombosis and Haemostasis, 2014, 112, 727-735.	1.8	102
74	Nailfold capillaroscopy in systemic sclerosis: Data from the EULAR scleroderma trials and research (EUSTAR) database. Microvascular Research, 2013, 89, 122-128.	1.1	101
75	Protection from experimental autoimmune diabetes in the non-obese diabetic mouse with soluble interleukin-1 receptor. European Journal of Immunology, 1994, 24, 1843-1847.	1.6	99
76	Antiphospholipid syndrome in 2014: more clinical manifestations, novel pathogenic players and emerging biomarkers. Arthritis Research and Therapy, 2014, 16, 209.	1.6	99
77	Risk factors for a first thrombotic event in antiphospholipid antibody carriers. A multicentre, retrospective follow-up study. Annals of the Rheumatic Diseases, 2009, 68, 397-399.	0.5	98
78	Characterization of the Endothelial Surface Proteins Recognized by Anti-Endothelial Antibodies in Primary and Secondary Autoimmune Vasculitis. Clinical Immunology and Immunopathology, 1994, 70, 211-216.	2.1	97
79	Pathogenic role of anti-Â2-glycoprotein I antibodies in antiphospholipid associated fetal loss: characterisation of Â2-glycoprotein I binding to trophoblast cells and functional effects of anti-Â2-glycoprotein I antibodies in vitro. Annals of the Rheumatic Diseases, 2004, 64, 462-467.	0.5	97
80	Autoantibodies and Prediction of Reproductive Failure. American Journal of Reproductive Immunology, 2006, 56, 337-344.	1.2	97
81	Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome. Immunologic Research, 2017, 65, 17-24.	1.3	97
82	The light and the dark sides of Interleukin-10 in immune-mediated diseases and cancer.. Cytokine and Growth Factor Reviews, 2016, 30, 87-93.	3.2	95
83	Obstetric and vascular antiphospholipid syndrome: same antibodies but different diseases?. Nature Reviews Rheumatology, 2018, 14, 433-440.	3.5	95
84	Autoantibodies to domain 1 of beta 2 glycoprotein 1: A promising candidate biomarker for risk management in antiphospholipid syndrome. Autoimmunity Reviews, 2012, 12, 313-317.	2.5	94
85	Newly Identified Antiatherosclerotic Activity of Methotrexate and Adalimumab: Complementary Effects on Lipoprotein Function and Macrophage Cholesterol Metabolism. Arthritis and Rheumatology, 2015, 67, 1155-1164.	2.9	94
86	Clinical Characterization of Antiphospholipid Syndrome by Detection of IgG Antibodies Against Î²₂â€Glycoprotein I Domain 1 and Domain 4/5: Ratio of Antiâ€“Domain 1 to Antiâ€“Domain 4/5 As a Useful New Biomarker for Antiphospholipid Syndrome. Arthritis and Rheumatology, 2015, 67, 2196-2204.	2.9	94
87	Endothelial cell activation by antiphospholipid antibodies. Clinical Immunology, 2004, 112, 169-174.	1.4	91
88	Recent advances in antiphospholipid antibodies and antiphospholipid syndromes in pediatric populations. Lupus, 2002, 11, 4-10.	0.8	90
89	Antifibroblast antibodies in systemic sclerosis induce fibroblasts to produce profibrotic chemokines, with partial exploitation of tollâ€like receptor 4. Arthritis and Rheumatism, 2008, 58, 3913-3923.	6.7	90
90	mTOR as a multifunctional therapeutic target in HIV infection. Drug Discovery Today, 2011, 16, 715-721.	3.2	90

#	Article	IF	Citations
91	Long-term treatment with rituximab in severe juvenile idiopathic arthritis-associated uveitis. British Journal of Ophthalmology, 2016, 100, 782-786.	2.1	90
92	Fetal outcome and recommendations of pregnancies in lupus nephritis in the 21st century. A prospective multicenter study. Journal of Autoimmunity, 2016, 74, 6-12.	3.0	89
93	Long-term Treatment with Golimumab for Severe Uveitis. Ocular Immunology and Inflammation, 2014, 22, 90-95.	1.0	88
94	Human anticardiolipin monoclonal autoantibodies cause placental necrosis and fetal loss in BALB/c mice. Arthritis and Rheumatism, 1998, 41, 1026-1039.	6.7	86
95	Anti-DNA antibodies: a diagnostic and prognostic tool for systemic lupus erythematosus?. Autoimmunity, 2005, 38, 39-45.	1.2	86
96	Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study. Journal of Autoimmunity, 2018, 86, 1-8.	3.0	86
97	Anti-Â2-glycoprotein I IgG antibodies from 1-year-old healthy children born to mothers with systemic autoimmune diseases preferentially target domain 4/5: might it be the reason for their 'innocent' profile?. Annals of the Rheumatic Diseases, 2011, 70, 380-383.	0.5	85
98	The X chromosome and the sex ratio of autoimmunity. Autoimmunity Reviews, 2012, 11, A531-A537.	2.5	85
99	The role of environmental estrogens and autoimmunity. Autoimmunity Reviews, 2012, 11, A493-A501.	2.5	85
100	Interleukinâ€17A+ Cell Counts Are Increased in Systemic Sclerosis Skin and Their Number Is Inversely Correlated With the Extent of Skin Involvement. Arthritis and Rheumatism, 2013, 65, 1347-1356.	6.7	85
101	Understanding and interpreting antinuclear antibody tests in systemic rheumatic diseases. Nature Reviews Rheumatology, 2020, 16, 715-726.	3.5	85
102	P2X7 receptor restrains pathogenic Tfh cell generation in systemic lupus erythematosus. Journal of Experimental Medicine, 2019, 216, 317-336.	4.2	83
103	The effects of a monoclonal antibody to interferon-Î³ on experimental autoimmune thyroiditis (EAT): prevention of disease and decrease of EAT-specific T cells. European Journal of Immunology, 1993, 23, 275-278.	1.6	82
104	Pathogenic mechanisms mediating antiphospholipid syndrome. Current Opinion in Rheumatology, 2001, 13, 377-382.	2.0	82
105	Patients with antiphospholipid syndrome display endothelial perturbation. Journal of Autoimmunity, 2010, 34, 105-110.	3.0	82
106	CIRCULATING SERUM LEVELS OF IL-1ra IN PATIENTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS ARE NORMAL DURING REMISSION PHASES BUT SIGNIFICANTLY INCREASED EITHER DURING EXACERBATIONS OR IN RESPONSE TO IFN-Î² TREATMENT. Cytokine, 1996, 8, 395-400.	1.4	81
107	Integrative Analysis Reveals a Molecular Stratification of Systemic Autoimmune Diseases. Arthritis and Rheumatology, 2021, 73, 1073-1085.	2.9	81
108	Epilepsy as part of systemic lupus erythematosus and systemic antiphospholipid syndrome (Hughes) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	6.8	80

#	Article	IF	Citations
109	Maternal outcome in pregnant women with lupus nephritis. A prospective multicenter study. Journal of Autoimmunity, 2016, 74, 194-200.	3.0	80
110	Sodium fusidate and increased remission rate of insulin-dependent diabetes mellitus. Lancet, The, 1991, 337, 1292.	6.3	79
111	Antibodies to tissue-type plasminogen activator (tPA) in patients with antiphospholipid syndrome: evidence of interaction between the antibodies and the catalytic domain of tPA in 2 patients. Blood, 2004, 103, 2121-2126.	0.6	77
112	Antiphospholipid Antibodies Affect Human Endometrial Angiogenesis1. Biology of Reproduction, 2010, 83, 212-219.	1.2	77
113	Differences in serum and synovial CD4+ T cells and cytokine profiles to stratify patients with inflammatory osteoarthritis and rheumatoid arthritis. Arthritis Research and Therapy, 2017, 19, 103.	1.6	77
114	Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: a clinical observational study. Rheumatology, 2014, 53, 1570-1577.	0.9	76
115	Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases. Autoimmunity Reviews, 2011, 11, 35-39.	2.5	75
116	Cocaine-induced midline destructive lesions â€" An autoimmune disease?. Autoimmunity Reviews, 2013, 12, 496-500.	2.5	75
117	Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis. Arthritis and Rheumatology, 2019, 71, 1553-1570.	2.9	75
118	Complement activation in anti-phospholipid syndrome: A clue for an inflammatory process?. Journal of Autoimmunity, 2007, 28, 160-164.	3.0	74
119	Th17 cells favor inflammatory responses while inhibiting type I collagen deposition by dermal fibroblasts: differential effects in healthy and systemic sclerosis fibroblasts. Arthritis Research and Therapy, 2013, 15, R151.	1.6	74
120	Blood levels of transforming growth factor-beta 1 (TGF-Î²1) are elevated in both relapsing remitting and chronic progressive multiple sclerosis (MS) patients and are further augmented by treatment with interferon-beta 1b (IFN-Î²1b). Clinical and Experimental Immunology, 1998, 113, 96-99.	1.1	72
121	Antibodies to endothelial cells in primary vasculitides mediate in vitro endothelial cytotoxicity in the presence of normal peripheral blood mononuclear cells. Clinical Immunology and Immunopathology, 1992, 63, 267-274.	2.1	71
122	Autoantibodies against Protective Moleculesâ€"C1q, Câ€Reactive Protein, Serum Amyloid P, Mannoseâ€Binding Lectin, and Apolipoprotein A1. Annals of the New York Academy of Sciences, 2007, 1108, 227-239.	1.8	71
123	Cutaneous Manifestations of ANCA-Associated Small Vessels Vasculitis. Clinical Reviews in Allergy and Immunology, 2017, 53, 428-438.	2.9	71
124	Treatment with rapamycin ameliorates clinical and histological signs of protracted relapsing experimental allergic encephalomyelitis in Dark Agouti rats and induces expansion of peripheral CD4+CD25+Foxp3+ regulatory T cells. Journal of Autoimmunity, 2009, 33, 135-140.	3.0	70
125	Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies. Rheumatology, 2014, 53, 1664-1668.	0.9	70
126	Methotrexate for the treatment of rheumatoid arthritis in the biologic era: Still an â€œanchorâ€•drug?. Autoimmunity Reviews, 2014, 13, 1102-1108.	2.5	70

#	Article	IF	Citations
127	Standardization of autoantibody testing: a paradigm for serology in rheumatic diseases. Nature Reviews Rheumatology, 2014, 10, 35-43.	3.5	70
128	Placental Thrombosis and Fetal Loss After Passive Transfer of Mouse Lupus Monoclonal or Human Polyclonal Anti-Cardiolipin Antibodies in Pregnant Naive BALB/c Mice. Scandinavian Journal of Immunology, 1995, 41, 427-432.	1.3	69
129	Role of the Interferonâ€Inducible Gene IFI16 in the Etiopathogenesis of Systemic Autoimmune Disorders. Annals of the New York Academy of Sciences, 2007, 1110, 47-56.	1.8	69
130	Increased levels of serum pentraxin 3, a novel cardiovascular biomarker, in patients with inflammatory rheumatic disease. Arthritis Care and Research, 2010, 62, 378-385.	1.5	69
131	Prevention of cardiovascular disease in rheumatoid arthritis. Autoimmunity Reviews, 2015, 14, 952-969.	2.5	69
132	Twelveâ€Year Retention Rate of Firstâ€Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Realâ€Life Data From a Local Registry. Arthritis Care and Research, 2016, 68, 432-439.	1.5	69
133	Haemostatic and inflammatory biomarkers in advanced chronic heart failure: role of oral anticoagulants and successful heart transplantation. British Journal of Haematology, 2004, 126, 85-92.	1.2	68
134	Inflammatory response and the endothelium. Thrombosis Research, 2004, 114, 329-334.	0.8	68
135	Pathogenesis of the antiphospholipid syndrome: An additional example of the mosaic of autoimmunity. Journal of Autoimmunity, 2008, 30, 99-103.	3.0	68
136	Anti-beta 2 glycoprotein I antibodies and the risk of myocardial infarction in young premenopausal women. Journal of Thrombosis and Haemostasis, 2007, 5, 2421-2428.	1.9	67
137	Complement activation in antiphospholipid syndrome and its inhibition to prevent rethrombosis after arterial surgery. Blood, 2016, 127, 365-367.	0.6	67
138	A new molecular classification to drive precision treatment strategies in primary SjÃ¶grenâ€™s syndrome. Nature Communications, 2021, 12, 3523.	5.8	67
139	Association of STAT4 and BLK, but not BANK1 or IRF5, with primary antiphospholipid syndrome. Arthritis and Rheumatism, 2009, 60, 2468-2471.	6.7	66
140	Measuring IgA Anti-Î²2-Glycoprotein I and IgG/IgA Anti-Domain I Antibodies Adds Value to Current Serological Assays for the Antiphospholipid Syndrome. PLoS ONE, 2016, 11, e0156407.	1.1	66
141	Prevalence and clinical significance of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. Annals of the Rheumatic Diseases, 2002, 61, 608-611.	0.5	65
142	The role of anti-endothelial cell antibodies in Kawasaki disease -in vitro and in vivo studies. Clinical and Experimental Immunology, 2002, 130, 233-240.	1.1	64
143	A novel autoantigen to differentiate limited cutaneous systemic sclerosis from diffuse cutaneous systemic sclerosis: The interferon-inducible gene IFI16. Arthritis and Rheumatism, 2006, 54, 3939-3944.	6.7	64
144	Toll-like receptors: another player in the pathogenesis of the anti-phospholipid syndrome. Lupus, 2008, 17, 938-943.	0.8	63

#	Article	IF	Citations
145	Fluvastatin treatment inhibits leucocyte adhesion and extravasation in models of complement-mediated acute inflammation. Clinical and Experimental Immunology, 2004, 135, 186-193.	1.1	62
146	Effect of Additional Treatments Combined with Conventional Therapies in Pregnant Patients with High-Risk Antiphospholipid Syndrome: A Multicentre Study. Thrombosis and Haemostasis, 2018, 47, 639-646.	1.8	62
147	HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome. Autoimmunity Reviews, 2018, 17, 1153-1168.	2.5	62
148	Inflammation and Accelerated Atherosclerosis: Basic Mechanisms. Rheumatic Disease Clinics of North America, 2005, 31, 355-362.	0.8	61
149	Characterization of biologically active antineutrophil cytoplasmic antibodies induced in mice:pathogenetic role in experimental vasculitis. Arthritis and Rheumatism, 1995, 38, 1375-1381.	6.7	60
150	Otorhinolaryngological manifestations in granulomatosis with polyangiitis (Wegener's). Autoimmunity Reviews, 2013, 12, 501-505.	2.5	60
151	The treatment of anti-phospholipid syndrome: A comprehensive clinical approach. Journal of Autoimmunity, 2018, 90, 1-27.	3.0	60
152	Beyond thrombosis: Anti-Î²2GPI domain 1 antibodies identify late pregnancy morbidity in anti-phospholipid syndrome. Journal of Autoimmunity, 2018, 90, 76-83.	3.0	60
153	Prevalence and Thrombotic Risk Assessment of Anti-Î²2 Glycoprotein I Domain I Antibodies: A Systematic Review. Seminars in Thrombosis and Hemostasis, 2018, 44, 466-474.	1.5	60
154	Development of a New International Antiphospholipid Syndrome Classification Criteria Phase I/II Report: Generation and Reduction of Candidate Criteria. Arthritis Care and Research, 2021, 73, 1490-1501.	1.5	60
155	Autoantibodies and SARS-CoV2 infection: The spectrum from association to clinical implication: Report of the 15th Dresden Symposium on Autoantibodies. Autoimmunity Reviews, 2022, 21, 103012.	2.5	60
156	Ferritin in the antiphospholipid syndrome and its catastrophic variant (cAPS). Lupus, 2013, 22, 1327-1335.	0.8	59
157	New Tests to Detect Antiphospholipid Antibodies: Anti-DomainÂI Beta-2-Glycoprotein-I Antibodies. Current Rheumatology Reports, 2014, 16, 402.	2.1	59
158	Prevention of diabetes in BB/Wor rats treated with monoclonal antibodies to interferon-Î³. Lancet, The, 1990, 336, 319.	6.3	58
159	Celiac Disease during Interferon Treatment. Annals of Internal Medicine, 1999, 131, 157.	2.0	58
160	Anti-phospholipid induced murine fetal loss: Novel protective effect of a peptide targeting the Î²2 glycoprotein I phospholipid-binding site. Implications for human fetal loss. Journal of Autoimmunity, 2012, 38, J209-J215.	3.0	58
161	Standards and reference materials for the anticardiolipin and anti-Î²2glycoprotein I assays: A report of recommendations from the APL Task Force at the 13th International Congress on Antiphospholipid Antibodies. Clinica Chimica Acta, 2012, 413, 358-360.	0.5	58
162	Interstitial lung disease outcomes by high-resolution computed tomography (HRCT) in Anti-Jo1 antibody-positive polymyositis patients: A single centre study and review of the literature. Autoimmunity Reviews, 2012, 11, 335-340.	2.5	58

#	Article	IF	Citations
163	Heterogeneity of immune responsiveness in healthy elderly subjects. Clinical Immunology and Immunopathology, 1988, 47, 142-151.	2.1	57
164	Prevalence and clinical correlations of antibodies against six beta2-glycoprotein-I-related peptides in the antiphospholipid syndrome. Journal of Clinical Immunology, 2003, 23, 377-383.	2.0	57
165	Anti-phosphatidylserine/prothrombin antibodies: an additional diagnostic marker for APS?. Immunologic Research, 2013, 56, 432-438.	1.3	57
166	Antimitochondrial (pyruvate dehydrogenase) autoantibodies in autoimmune rheumatic diseases. Journal of Clinical Immunology, 1992, 12, 201-209.	2.0	56
167	Alterations in the immune system of children from mothers treated with immunosuppressive agents during pregnancy. Toxicology Letters, 2004, 149, 155-162.	0.4	56
168	Pregnancies Complicated with Antiphospholipid Syndrome: The Pathogenic Mechanism of Antiphospholipid Antibodies: A Review of the Literature. Annals of the New York Academy of Sciences, 2007, 1108, 505-514.	1.8	56
169	Rituximab for Uveitis. Ophthalmology, 2011, 118, 223-224.	2.5	56
170	Towards a better understanding of the clinical association of anti-DFS70 autoantibodies. Autoimmunity Reviews, 2016, 15, 198-201.	2.5	56
171	The Use of Cyclosporine A in Rheumatology: a 2016 Comprehensive Review. Clinical Reviews in Allergy and Immunology, 2017, 52, 401-423.	2.9	56
172	Prevalence of Anti-cardiolipin, Anti-2Glycoprotein I, and Anti-prothrombin Antibodies in Young Patients with Epilepsy. Epilepsia, 2002, 43, 52-59.	2.6	55
173	Vitamin D and antiphospholipid syndrome. Lupus, 2012, 21, 736-740.	0.8	55
174	Neuroimmune crosstalk in the pathophysiology of hypertension. Nature Reviews Cardiology, 2019, 16, 476-490.	6.1	55
175	The Ped-APS Registry: the antiphospholipid syndrome in childhood. Lupus, 2009, 18, 894-899.	0.8	54
176	Antiphospholipid syndrome and systemic lupus erythematosus: are they separate entities or just clinical presentations on the same scale?. Current Opinion in Rheumatology, 2009, 21, 495-500.	2.0	54
177	Redistribution of the nuclear protein IFI16 into the cytoplasm of ultraviolet B-exposed keratinocytes as a mechanism of autoantigen processing. British Journal of Dermatology, 2011, 164, 282-290.	1.4	54
178	Anti-phospholipid antibody mediated fetal loss: still an open question from a pathogenic point of view. Lupus, 2010, 19, 453-456.	0.8	53
179	Automated tests of ANA immunofluorescence as throughput autoantibody detection technology: strengths and limitations. BMC Medicine, 2014, 12, 38.	2.3	53
180	Evaluation of phosphatidylserine-dependent antiprothrombin antibody testing for the diagnosis of antiphospholipid syndrome: results of an international multicentre study. Lupus, 2017, 26, 266-276.	0.8	53

#	Article	IF	Citations
181	Antibodies to endothelial cells identify myocardial damage and predict development of coronary artery disease in patients with transplanted hearts. Human Immunology, 1999, 60, 826-832.	1.2	52
182	ESSENTIAL PATHOGENETIC ROLE FOR INTERFERON (IFN-)Î³ IN CONCANAVALIN A-INDUCED T CELL-DEPENDENT HEPATITIS: EXACERBATION BY EXOGENOUS IFN-Î³ AND PREVENTION BY IFN-Î³ RECEPTOR-IMMUNOGLOBULIN FUSION PROTEIN. Cytokine, 2000, 12, 315-323.	1.4	52
183	Antiphospholipid antibodies as cause of pregnancy loss. Lupus, 2004, 13, 649-652.	0.8	52
184	Pathogenic role of anti-Î²2-glycoprotein I antibodies on human placenta: functional effects related to implantation and roles of heparin. Human Reproduction Update, 2007, 13, 189-196.	5.2	52
185	Chronic urticaria: A disease at a crossroad between autoimmunity and coagulation. Autoimmunity Reviews, 2007, 7, 71-76.	2.5	52
186	Autoimmune or auto-inflammatory syndrome induced by adjuvants (ASIA): Old truths and a new syndrome?. Journal of Autoimmunity, 2011, 36, 1-3.	3.0	52
187	Prolactin and Autoimmunity. Clinical Reviews in Allergy and Immunology, 2012, 42, 189-198.	2.9	52
188	Î²2-glycoprotein I, lipopolysaccharide and endothelial TLR4: Three players in the two hit theory for anti-phospholipid-mediated thrombosis. Journal of Autoimmunity, 2014, 55, 42-50.	3.0	52
189	AutoAbSC.Org â€" Autoantibody Standardization Committee in 2006. Autoimmunity Reviews, 2007, 6, 577-580.	2.5	51
190	Decreased expression of heparinâ€binding epidermal growth factorâ€"like growth factor as a newly identified pathogenic mechanism of antiphospholipidâ€mediated defective placentation. Arthritis and Rheumatism, 2010, 62, 1504-1512.	6.7	51
191	Anti-CarP antibodies as promising marker to measure joint damage and disease activity in patients with rheumatoid arthritis. Immunologic Research, 2015, 61, 24-30.	1.3	51
192	Choroidal impairment and macular thinning in patients with systemic sclerosis: The acute study. Microvascular Research, 2015, 97, 31-36.	1.1	51
193	Longterm Outcome of Patients with Primary Antiphospholipid Syndrome: A Retrospective Multicenter Study. Journal of Rheumatology, 2017, 44, 1165-1172.	1.0	51
194	Pathogenic Role of Complement in Antiphospholipid Syndrome and Therapeutic Implications. Frontiers in Immunology, 2018, 9, 1388.	2.2	51
195	Toxicological and Immune Findings in Workers Exposed to Pentachlorophenol (PCP). Archives of Environmental Health, 1993, 48, 81-88.	0.4	50
196	Concomitant disappearance of electrocardiographic abnormalities and of acquired maternal autoantibodies during the first year of life in infants who had QT interval prolongation and anti-SSA/Ro positivity without congenital heart block at birth. Arthritis and Rheumatism, 2003, 48, 266-268.	6.7	50
197	Innate immunity in the antiphospholipid syndrome: role of toll-like receptors in endothelial cell activation by antiphospholipid antibodies. Autoimmunity Reviews, 2004, 3, 510-515.	2.5	50
198	Humoral autoimmunity against endothelium: theory or reality?. Trends in Immunology, 2005, 26, 275-281.	2.9	50

#	Article	IF	Citations
199	Antinucleosome antibodies in primary antiphospholipid syndrome: A hint at systemic autoimmunity?. Journal of Autoimmunity, 2008, 30, 51-57.	3.0	50
200	Obstetric antiphospholipid syndrome: A recent classification for an old defined disorder. Autoimmunity Reviews, 2014, 13, 901-908.	2.5	50
201	Autoantibodies to coagulation factors: From pathophysiology to diagnosis and therapy. Autoimmunity Reviews, 2014, 13, 40-48.	2.5	50
202	ANTIPHOSPHOLIPID ANTIBODIES AND THE ENDOTHELIUM. Rheumatic Disease Clinics of North America, 2001, 27, 587-602.	0.8	49
203	Pathogenic anti-nucleosome antibodies. Lupus, 2008, 17, 431-436.	0.8	49
204	Maternal and sibling microchimerism in twins and triplets discordant for neonatal lupus syndrome-congenital heart block. Rheumatology, 2005, 44, 187-191.	0.9	48
205	X Monosomy in Female Systemic Lupus Erythematosus. Annals of the New York Academy of Sciences, 2007, 1110, 84-91.	1.8	48
206	Treatment of Thrombotic Antiphospholipid Syndrome: The Rationale of Current Managementâ€"An Insight into Future Approaches. Journal of Immunology Research, 2015, 2015, 1-20.	0.9	48
207	IL-22 capacitates dermal fibroblast responses to TNF in scleroderma. Annals of the Rheumatic Diseases, 2016, 75, 1697-1705.	0.5	48
208	ANA as an entry criterion for the classification of SLE. Autoimmunity Reviews, 2019, 18, 102400.	2.5	48
209	Pregnancy and autoimmunity: Maternal treatment and maternal disease influence on pregnancy outcome. Autoimmunity Reviews, 2005, 4, 423-428.	2.5	47
210	Predictive, protective, orphan autoantibodies: The example of anti-phospholipid antibodies. Autoimmunity Reviews, 2008, 7, 585-587.	2.5	46
211	Systemic vasculitis and pregnancy: A multicenter study on maternal and neonatal outcome of 65 prospectively followed pregnancies. Autoimmunity Reviews, 2015, 14, 686-691.	2.5	46
212	In vivo immunopotentiating activity of thymopentin in aging humans: Increase of Il-2 production. Clinical Immunology and Immunopathology, 1987, 42, 151-159.	2.1	45
213	Human monoclonal anti-endothelial cell IgG-derived from a systemic lupus erythematosus patient binds and activates human endothelium in vitro. International Immunology, 2001, 13, 349-357.	1.8	45
214	Peripheral Blood Mononuclear Cell Î²-Endorphin Concentration Is Decreased in Chronic Fatigue Syndrome and Fibromyalgia but Not in Depression: Preliminary Report. Clinical Journal of Pain, 2002, 18, 270-273.	0.8	45
215	Endothelium as a target for antiphospholipid antibodies. Immunobiology, 2003, 207, 29-36.	0.8	45
216	European Attempts to Set Guidelines for Improving Diagnostics of Autoimmune Rheumatic Disorders. Lupus, 2006, 15, 391-396.	0.8	45

#	Article	IF	Citations
217	Hypomethylating Agent 5â€Azaâ€2â€²â€deoxycytidine (DAC) Ameliorates Multiple Sclerosis in Mouse Models. Journal of Cellular Physiology, 2014, 229, 1918-1925.	2.0	45
218	Essential pathogenic role for endogenous interferon-gamma (IFN-Î³) during disease onset phase of murine experimental autoimmune orchitis. I. In vivo studies. Clinical and Experimental Immunology, 1998, 111, 513-520.	1.1	44
219	Lupus Anticoagulants and Their Relationship with the Inhibitors against Coagulation Factor VIII: Considerations on the Differentiation between the 2 Circulating Anticoagulants. Clinical Chemistry, 2005, 51, 1883-1885.	1.5	44
220	Antiphospholipid Antibodies Affect Human Endometrial Angiogenesis: Protective Effect of a Synthetic Peptide (TIFI) Mimicking the Phospholipid Binding Site of Î²₂glycoprotein I. American Journal of Reproductive Immunology, 2013, 70, 299-308.	1.2	44
221	Serum antinuclear and extractable nuclear antigen antibody prevalence and associated morbidity and mortality in the general population over 15years. Autoimmunity Reviews, 2016, 15, 162-166.	2.5	44
222	Disease activity assessment of rheumatic diseases during pregnancy: a comprehensive review of indices used in clinical studies. Autoimmunity Reviews, 2019, 18, 164-176.	2.5	44
223	Multiple-Organ Complement Deposition on Vascular Endothelium in COVID-19 Patients. Biomedicines, 2021, 9, 1003.	1.4	44
224	Baseline ultrasound examination as possible predictor of relapse in patients affected by juvenile idiopathic arthritis (JIA). Annals of the Rheumatic Diseases, 2018, 77, 1426-1431.	0.5	42
225	Age-related changes of beta-endorphin and cholecystokinin in human and rat mononuclear cells. Peptides, 1991, 12, 1353-1356.	1.2	41
226	Multicenter Evaluation Study on a New HEp2 ANA Screening Enzyme Immune Assay. Journal of Autoimmunity, 1999, 13, 89-93.	3.0	41
227	Venous thromboembolism in the antiphospholipid syndrome: management guidelines for secondary prophylaxis. Lupus, 2003, 12, 504-507.	0.8	41
228	Antiphospholipid syndrome dilemmas still to be solved: 2008 status: Table 1. Annals of the Rheumatic Diseases, 2008, 67, 438-442.	0.5	41
229	The proapoptotic activity of the Interferon-inducible gene IFI16 provides new insights into its etiopathogenetic role in autoimmunity. Journal of Autoimmunity, 2010, 35, 114-123.	3.0	41
230	Obstetric and vascular APS: Same autoantibodies but different diseases?. Lupus, 2012, 21, 708-710.	0.8	41
231	EUREKA algorithm predicts obstetric risk and response to treatment in women with different subsets of anti-phospholipid antibodies. Rheumatology, 2021, 60, 1114-1124.	0.9	41
232	Antifibroblast antibodies from systemic sclerosis patients are internalized by fibroblasts via a caveolin-linked pathway. Arthritis and Rheumatism, 2002, 46, 1595-1601.	6.7	40
233	Anti-beta 2 glycoprotein I antibodies in centenarians. Experimental Gerontology, 2004, 39, 1459-1465.	1.2	40
234	Electrocardiographic abnormalities in infants born from mothers with autoimmune diseases a multicentre prospective study. Rheumatology, 2007, 46, 1285-1289.	0.9	40

#	Article	IF	Citations
235	Rheumatoid Arthritis: A Female Challenge. Women's Health, 2008, 4, 195-201.	0.7	40
236	European attempts for the standardisation of the antiphospholipid antibodies. Lupus, 2009, 18, 913-919.	0.8	40
237	New insight into antiphospholipid syndrome: antibodies to Î²2glycoprotein I-domain 5 fail to induce thrombi in rats. Haematologica, 2019, 104, 819-826.	1.7	40
238	Complement Activation and Pregnancy Failure. Clinical Reviews in Allergy and Immunology, 2010, 39, 153-159.	2.9	39
239	High IL-17E and Low IL-17C Dermal Expression Identifies a Fibrosis-Specific Motif Common to Morphea and Systemic Sclerosis. PLoS ONE, 2014, 9, e105008.	1.1	39
240	First Report of the Italian Registry on Immune-Mediated Congenital Heart Block (Lu.Ne Registry). Frontiers in Cardiovascular Medicine, 2019, 6, 11.	1.1	39
241	Impact of in utero environment on the offspring of lupus patients. Lupus, 2006, 15, 801-807.	0.8	38
242	Updating on the Pathogenic Mechanisms 5 of the Antiphospholipid Antibodies-Associated Pregnancy Loss. Clinical Reviews in Allergy and Immunology, 2008, 34, 332-337.	2.9	38
243	The interplay between the antiphospholipid syndrome and systemic lupus erythematosus. Autoimmunity, 2009, 42, 257-259.	1.2	38
244	Pregnancy in autoimmune rheumatic diseases: The importance of counselling for old and new challenges. Autoimmunity Reviews, 2010, 10, 51-54.	2.5	38
245	Autoantibody Profile of Primary Sclerosing Cholangitis. Pathobiology, 1995, 63, 76-82.	1.9	37
246	<scp>VGX</scp>â€1027 modulates genes involved in lipopolysaccharideâ€induced <scp>T</scp>ollâ€like receptor 4 activation and in a murine model of systemic lupus erythematosus. Immunology, 2014, 142, 594-602.	2.0	37
247	IL-10â€“producing forkhead box protein 3â€“negative regulatory TÂcells inhibit B-cell responses andÂare involved in systemic lupus erythematosus. Journal of Allergy and Clinical Immunology, 2016, 137, 318-321.e5.	1.5	37
248	Epigenetics and Systemic Lupus Erythematosus: Unmet Needs. Clinical Reviews in Allergy and Immunology, 2016, 50, 367-376.	2.9	37
249	The Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibodyâ€“Positive Patients: Results From the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Clinical Database and Repository. Arthritis Care and Research, 2019, 71, 134-141.	1.5	37
250	European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. Annals of the Rheumatic Diseases, 2021, 80, 775-781.	0.5	37
251	EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19. Annals of the Rheumatic Diseases, 2021, 80, 698-706.	0.5	37
252	Modulation of Endothelial Cell Function by Antiphospholipid Antibodies. Lupus, 1996, 5, 448-450.	0.8	35

#	Article	IF	Citations
253	Primary anti-phospholipid syndrome: any role for serum complement levels in predicting pregnancy complications?. Rheumatology, 2012, 51, 2186-2190.	0.9	35
254	Skin Manifestations Induced by TNF-Alpha Inhibitors in Juvenile Idiopathic Arthritis. Clinical Reviews in Allergy and Immunology, 2012, 42, 131-134.	2.9	35
255	Update on the pathogenesis and treatment of the antiphospholipid syndrome. Current Opinion in Rheumatology, 2015, 27, 476-482.	2.0	35
256	Purified IgG from Patients with Obstetric but not IgG from Nonâ€obstetric Antiphospholipid Syndrome Inhibit Trophoblast Invasion. American Journal of Reproductive Immunology, 2015, 73, 390-401.	1.2	35
257	Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. Annals of the Rheumatic Diseases, 2020, 79, 1333-1339.	0.5	35
258	Immune function in children born to mothers with autoimmune diseases and exposed in utero to immunosuppressants. Lupus, 2007, 16, 651-656.	0.8	34
259	New oral anticoagulants in thrombotic antiphospholipid syndrome. Lupus, 2014, 23, 1279-1282.	0.8	34
260	Î²2 Glycoprotein I Recognition Drives Th1 Inflammation in Atherosclerotic Plaques of Patients with Primary Antiphospholipid Syndrome. Journal of Immunology, 2017, 198, 2640-2648.	0.4	34
261	Cytokines and Soluble Receptor Changes in the Transition from Primary to Early Chronic HIV Type 1 Infection. AIDS Research and Human Retroviruses, 1996, 12, 325-331.	0.5	33
262	Enhanced monocyte expression of tissue factor by oxidative stress in patients with antiphospholipid antibodies: effect of antioxidant treatment. Journal of Thrombosis and Haemostasis, 2003, 1, 523-531.	1.9	33
263	Simultaneous Automated Screening and Confirmatory Testing for Vasculitis-Specific ANCA. PLoS ONE, 2014, 9, e107743.	1.1	33
264	Anti-beta-2 glycoprotein I epitope specificity: from experimental models to diagnostic tools. Lupus, 2016, 25, 905-910.	0.8	33
265	Immune complexes containing scleroderma-specific autoantibodies induce a profibrotic and proinflammatory phenotype in skin fibroblasts. Arthritis Research and Therapy, 2018, 20, 187.	1.6	33
266	Triple Antiphospholipid (aPL) Antibodies Positivity Is Associated With Pregnancy Complications in aPL Carriers: A Multicenter Study on 62 Pregnancies. Frontiers in Immunology, 2019, 10, 1948.	2.2	33
267	Targeting CD34+ cells of the inflamed synovial endothelium by guided nanoparticles for the treatment of rheumatoid arthritis. Journal of Autoimmunity, 2019, 103, 102288.	3.0	33
268	Scleroderma-specific autoantibodies embedded in immune complexes mediate endothelial damage: an early event in the pathogenesis of systemic sclerosis. Arthritis Research and Therapy, 2020, 22, 265.	1.6	33
269	Vaccinations in adults with rheumatoid arthritis in an era of new disease-modifying anti-rheumatic drugs. Clinical and Experimental Rheumatology, 2018, 36, 317-328.	0.4	33
270	Anti-mitochondrial M5 type antibody represents one of the serological markers for anti-phospholipid syndrome distinct from anti-cardiolipin and anti-Î²2 -glycoprotein I antibodies. Clinical and Experimental Immunology, 1998, 112, 144-151.	1.1	32

#	Article	IF	Citations
271	Anti-fibroblast antibodies detected by cell-based ELISA in systemic sclerosis enhance the collagenolytic activity and matrix metalloproteinase-1 production in dermal fibroblasts. Rheumatology, 2007, 46, 1779-1785.	0.9	32
272	Hyperferritinemia is Associated with Serologic Antiphospholipid Syndrome in SLE Patients. Clinical Reviews in Allergy and Immunology, 2013, 44, 23-30.	2.9	32
273	Antiphospholipid antibodies detected by line immunoassay differentiate among patients with antiphospholipid syndrome, with infections and asymptomatic carriers. Arthritis Research and Therapy, 2016, 18, 111.	1.6	32
274	Eightâ€Year Retention Rate of Firstâ€Line Tumor Necrosis Factor Inhibitors in Spondyloarthritis: A Multicenter Retrospective Analysis. Arthritis Care and Research, 2017, 69, 867-874.	1.5	32
275	In vitro production of type 1 and type 2 cytokines by peripheral blood mononuclear cells from high-risk HIV-negative intravenous drug users. Aids, 1995, 9, 691-694.	1.0	31
276	The impact of treatment of the fetus by maternal therapy on the fetal and postnatal outcomes for fetuses diagnosed with isolated complete atrioventricular block. Cardiology in the Young, 2009, 19, 282.	0.4	31
277	The challenges of lupus anticoagulants. Expert Review of Hematology, 2016, 9, 389-400.	1.0	31
278	Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences. Clinical Rheumatology, 2017, 36, 1747-1755.	1.0	31
279	Evaluation of Endothelial Function by Flow-Mediated Dilation: a Comprehensive Review in Rheumatic Disease. Archivum Immunologiae Et Therapiae Experimentalis, 2017, 65, 463-475.	1.0	31
280	Unending story of the indirect immunofluorescence assay on HEp-2 cells: old problems and new solutions?. Annals of the Rheumatic Diseases, 2019, 78, e46-e46.	0.5	31
281	Antiglutamate Receptor Antibodies and Cognitive Impairment in Primary Antiphospholipid Syndrome and Systemic Lupus Erythematosus. Frontiers in Immunology, 2016, 7, 5.	2.2	30
282	The Complement System in the Pathophysiology of Pregnancy and in Systemic Autoimmune Rheumatic Diseases During Pregnancy. Frontiers in Immunology, 2020, 11, 2084.	2.2	30
283	Diagnostic accuracy of currently available anti-double-stranded DNA antibody assays. An Italian multicentre study. Clinical and Experimental Rheumatology, 2011, 29, 50-6.	0.4	30
284	Overview on Anticardiolipin ELISA Standardization. Journal of Autoimmunity, 2000, 15, 195-197.	3.0	29
285	Anti-Inflammatory and Immunomodulating Properties of Statins: An Additional Tool for the Therapeutic Approach of Systemic Autoimmune Diseases?. Clinical Reviews in Allergy and Immunology, 2002, 23, 263-278.	2.9	29
286	Neonatal lupus: fetal myocarditis progressing to atrioventricular block in triplets. Lupus, 2003, 12, 775-778.	0.8	29
287	Antiphospholipid antibodies and risk of intrauterine late fetal death. Acta Obstetricia Et Gynecologica Scandinavica, 1994, 73, 389-392.	1.3	28
288	The two hit hypothesis in the antiphospholipid syndrome: acute ischaemic heart involvement after valvular replacement despite anticoagulation in a patient with secondary APS. Lupus, 2003, 12, 851-853.	0.8	28

#	Article	IF	Citations
289	Anti-Beta-2 Glycoprotein I Antibodies Affect Bcl-2 and Bax Trophoblast Expression without Evidence of Apoptosis. Annals of the New York Academy of Sciences, 2006, 1069, 364-376.	1.8	28
290	EASI The European Autoimmunity Standardisation Initiative: A New Initiative that Can Contribute to Agreed Diagnostic Models of Diagnosing Autoimmune Disorders throughout Europe. Annals of the New York Academy of Sciences, 2007, 1109, 138-144.	1.8	28
291	Evaluation of Current Methods for the Measurement of Serum Anti Double-Stranded DNA Antibodies. Annals of the New York Academy of Sciences, 2007, 1109, 401-406.	1.8	28
292	Pro-inflammatory genotype as a risk factor for aPL-associated thrombosis: Report of a family with multiple anti-phospholipid positive members. Journal of Autoimmunity, 2009, 32, 60-63.	3.0	28
293	Prolactinâ€™s role in the pathogenesis of the antiphospholipid syndrome. Lupus, 2010, 19, 1515-1519.	0.8	28
294	New strategies to address the pharmacodynamics and pharmacokinetics of tumor necrosis factor (TNF) inhibitors: A systematic analysis. Autoimmunity Reviews, 2015, 14, 812-829.	2.5	28
295	Challenges and treatment options for rheumatoid arthritis during pregnancy. Expert Opinion on Pharmacotherapy, 2016, 17, 1539-1547.	0.9	28
296	Flares After Withdrawal of Biologic Therapies in Juvenile Idiopathic Arthritis: Clinical and Laboratory Correlates of Remission Duration. Arthritis Care and Research, 2018, 70, 1046-1051.	1.5	28
297	Blood Cell-Bound C4d as a Marker of Complement Activation in Patients With the Antiphospholipid Syndrome. Frontiers in Immunology, 2019, 10, 773.	2.2	28
298	Antiphospholipid antibody profile: implications for the evaluation and management of patients. Lupus, 2010, 19, 432-435.	0.8	27
299	Immune-mediated inflammatory reactions and tumors as skin side effects of inflammatory bowel disease therapy. Autoimmunity, 2014, 47, 146-153.	1.2	27
300	In vivo treatment with a monoclonal antibody to interferon-gamma neither affects the survival nor the incidence of lupus-nephritis in the MRL/lpr-lpr mouse. Immunopharmacology, 1992, 24, 11-16.	2.0	26
301	Endogenous interleukinâ€12 only plays a key pathogenetic role in nonâ€obese diabetic mouse diabetes during the very early stages of the disease. Immunology, 1999, 97, 367-370.	2.0	26
302	Activation of the immune system and coronary artery disease: the role of anti-endothelial cell antibodies. Atherosclerosis, 2001, 154, 429-436.	0.4	26
303	Immunization of naive BALB/c mice with human ?2-Glycoprotein I breaks tolerance to the murine molecule. Arthritis and Rheumatism, 2002, 46, 1399-1404.	6.7	26
304	Pregnancy Complications of the Antiphospholipid Syndrome. Autoimmunity, 2003, 36, 27-32.	1.2	26
305	Statins and autoimmune diseases. Autoimmunity Reviews, 2005, 4, 123-129.	2.5	26
306	Variable effects of cyclophosphamide in rodent models of experimental allergic encephalomyelitis. Clinical and Experimental Immunology, 2009, 159, 159-168.	1.1	26

#	Article	IF	Citations
307	Low levels of vitamin D are common in primary antiphospholipid syndrome with thrombotic disease. Reumatismo, 2012, 64, 307-13.	0.4	26
308	Tumour Necrosis Factor Î± Antagonists in the Treatment of Rheumatoid Arthritis: An Immunological Perspective. BioDrugs, 2014, 28, 5-13.	2.2	26
309	Management of Thrombotic Antiphospholipid Syndrome. Seminars in Thrombosis and Hemostasis, 2018, 44, 419-426.	1.5	26
310	Primary antiphospholipid syndrome and antiphospholipid syndrome associated to systemic lupus: Are they different entities?. Autoimmunity Reviews, 2018, 17, 739-745.	2.5	26
311	2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19. Annals of the Rheumatic Diseases, 2022, 81, 34-40.	0.5	26
312	Thrombotic events in patients with systemic sclerosis treated with iloprost. Arthritis and Rheumatism, 1998, 41, 559-560.	6.7	25
313	Characterization of murine monoclonal anti-endothelial cell antibodies (AECA) produced by idiotypic manipulation with human AECA. International Immunology, 1998, 10, 861-868.	1.8	25
314	Transforming growth factor Î²1 in the pathogenesis of autoimmune congenital complete heart block: Lesson from twins and triplets discordant for the disease. Arthritis and Rheumatism, 2006, 54, 356-359.	6.7	25
315	Are the Current Attempts at Standardization of Antiphospholipid Antibodies Still Useful? Emerging Technologies Signal a Shift in Direction. Seminars in Thrombosis and Hemostasis, 2008, 34, 356-360.	1.5	25
316	Type I interferon therapy and its role in autoimmunity. Autoimmunity, 2010, 43, 248-254.	1.2	25
317	Update on the current recommendations and outcomes in pregnant women with antiphospholipid syndrome. Expert Review of Clinical Immunology, 2014, 10, 1505-1517.	1.3	25
318	â€œDisease knowledge indexâ€•and perspectives on reproductive issues: A nationwide study on 398 women with autoimmune rheumatic diseases. Joint Bone Spine, 2019, 86, 475-481.	0.8	25
319	Lipid management in rheumatoid arthritis: a position paper of the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 104-114.	1.4	25
320	Biologics During Pregnancy and Breastfeeding Among Women With Rheumatic Diseases: Safety Clinical Evidence on the Road. Frontiers in Pharmacology, 2021, 12, 621247.	1.6	25
321	Correlation between islet cell antibodies and anti-cytomegalovirus IgM and IgG antibodies in healthy first-degree relatives of type 1 (insulin-dependent) diabetic patients. Clinical Immunology and Immunopathology, 1990, 55, 139-147.	2.1	24
322	Posttransplant Ischemia-Reperfusion Injury In Transplanted Heart Is Prevented By A Minibody to the Fifth Component of Complement. Transplantation, 2008, 86, 1445-1451.	0.5	24
323	Antiphospholipid antibodies mediate autoimmunity against dying cells. Autoimmunity, 2013, 46, 302-306.	1.2	24
324	Safety considerations when prescribing immunosuppression medication to pregnant women. Expert Opinion on Drug Safety, 2014, 13, 1591-1599.	1.0	24

#	Article	IF	Citations
325	Second generation analysis of antinuclear antibody (ANA) by combination of screening and confirmatory testing. Clinical Chemistry and Laboratory Medicine, 2015, 53, 1991-2002.	1.4	24
326	Gene expression profiling identifies distinct molecular signatures in thrombotic and obstetric antiphospholipid syndrome. Journal of Autoimmunity, 2018, 93, 114-123.	3.0	24
327	Plasma levels of soluble endothelial cell protein C receptor in patients with Wegenerâ€™s granulomatosis. Clinical and Experimental Immunology, 2002, 128, 187-194.	1.1	23
328	Role of anti-Î²2 glycoprotein I antibodies in antiphospholipid syndromeglycoprotein I antibodies in antiphospholipid syndrome. Clinical Reviews in Allergy and Immunology, 2007, 32, 67-73.	2.9	23
329	Detection of anti-IFI16 antibodies by ELISA: clinical and serological associations in systemic sclerosis. Rheumatology, 2011, 50, 674-681.	0.9	23
330	Toll-like receptor 4 and Î²₂ glycoprotein I interaction on endothelial cells. Lupus, 2014, 23, 1302-1304.	0.8	23
331	Novel Mechanisms of Action of the Biologicals in Rheumatic Diseases. Clinical Reviews in Allergy and Immunology, 2014, 47, 6-16.	2.9	23
332	Recognition and management of antiphospholipid syndrome. Current Opinion in Rheumatology, 2016, 28, 51-59.	2.0	23
333	Comparing Originator Biologics and Biosimilars: A Review of the Relevant Issues. Clinical Therapeutics, 2017, 39, 1026-1039.	1.1	23
334	The effects of a nonimmunogenic form of murine soluble interferon-gamma receptor on the development of autoimmune diabetes in the NOD mouse. Endocrinology, 1996, 137, 5567-5575.	1.4	23
335	Thromboprophylaxis in carriers of antiphospholipid antibodies (APL) without previous thrombosis: â€œProsâ€•and â€œConsâ€• Autoimmunity Reviews, 2012, 11, 568-571.	2.5	22
336	Diagnostic laboratory tests for systemic autoimmune rheumatic diseases: unmet needs towards harmonization. Clinical Chemistry and Laboratory Medicine, 2018, 56, 1743-1748.	1.4	22
337	In utero exposure to Azathioprine in autoimmune disease. Where do we stand?. Autoimmunity Reviews, 2020, 19, 102525.	2.5	22
338	Position paper of Italian rheumatologists on the use of biosimilar drugs. Clinical and Experimental Rheumatology, 2015, 33, 1-4.	0.4	22
339	Statins and autoimmune diseases. Lupus, 2005, 14, 765-768.	0.8	21
340	Nonorgan specific autoantibodies and heart damage. Lupus, 2005, 14, 656-659.	0.8	21
341	Skin autoimmunity and blood coagulation. Autoimmunity, 2010, 43, 189-194.	1.2	21
342	Cutting-Edge Issues in Coronary Disease and the Primary Antiphospholipid Syndrome. Clinical Reviews in Allergy and Immunology, 2013, 44, 51-56.	2.9	21

#	Article	IF	Citations
343	Does APS Impact Womenâ€™s Fertility?. Current Rheumatology Reports, 2017, 19, 33.	2.1	21
344	Antiphospholipid Antibody Assays in 2021: Looking for a Predictive Value in Addition to a Diagnostic One. Frontiers in Immunology, 2021, 12, 726820.	2.2	21
345	Role of antiphospholipid antibodies in the diagnosis of antiphospholipid syndrome. Journal of Translational Autoimmunity, 2021, 4, 100134.	2.0	21
346	COVID-19 and antiphospholipid antibodies: A position statement and management guidance from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION). Lupus, 2021, 30, 2276-2285.	0.8	21
347	Anti-ribosomal ribonucleoprotein autoantibodies in systemic lupus erythematosus. Journal of Clinical Immunology, 1984, 4, 45-54.	2.0	20
348	Abnormalities of in vitro immunoglobulin synthesis by peripheral blood lymphocytes from patients with essential mixed cryoglobulinemia. Clinical Immunology and Immunopathology, 1984, 33, 245-257.	2.1	20
349	Anti-rheumatic treatment is not associated with reduction of pentraxin 3 in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. PLoS ONE, 2017, 12, e0169830.	1.1	20
350	Standardization procedure for flow cytometry data harmonization in prospective multicenter studies. Scientific Reports, 2020, 10, 11567.	1.6	20
351	INFLUENZA VACCINATION WITH ADJUVANT RU41740 IN THE ELDERLY. Lancet, The, 1987, 329, 973.	6.3	19
352	Immunomodulating activity of RU 41740: In vitro and in vivo studies on human lymphocytes. International Journal of Immunopharmacology, 1987, 9, 185-190.	1.1	19
353	Endothelium as a target for anti-phospholipid antibodies and for therapeutical intervention. Autoimmunity Reviews, 2002, 1, 55-60.	2.5	19
354	Intracerebral haemorrhage, a possible presentation in Churg-Strauss syndrome: Case report and review of the literature. Journal of the Neurological Sciences, 2011, 301, 107-111.	0.3	19
355	Does polymorphysm of genes coding for pro-inflammatory mediators predict the clinical response to tnf alpha blocking agents? A review analysis of the literature. Autoimmunity Reviews, 2011, 10, 460-463.	2.5	19
356	Drug survival and reasons for discontinuation of the first course of biological therapy in 301 juvenile idiopathic arthritis patients. Reumatismo, 2014, 65, 278.	0.4	19
357	Prevention & treatment of obstetrical complications in APS: Is hydroxychloroquine the Holy Grail we are looking for?. Journal of Autoimmunity, 2016, 75, 1-5.	3.0	19
358	From autoantibody research to standardized diagnostic assays in the management of human diseases â€“ report of the 12th Dresden Symposium on Autoantibodies. Lupus, 2016, 25, 787-796.	0.8	19
359	Detection of early endothelial damage in patients with Raynaud's phenomenon. Microvascular Research, 2017, 113, 22-28.	1.1	19
360	Can we withdraw anticoagulation in patients with antiphospholipid syndrome after seroconvertion?. Autoimmunity Reviews, 2017, 16, 1109-1114.	2.5	19

#	Article	IF	Citations
361	Interleukin-17/Interleukin-21 and Interferon-Î³ producing T cells specific for Î²2 Glycoprotein I in atherosclerosis inflammation of systemic lupus erythematosus patients with antiphospholipid syndrome. Haematologica, 2019, 104, 2519-2527.	1.7	19
362	Enhanced percentage of CD5+ B lymphocytes in newly diagnosed IDDM patients. Immunology Letters, 1990, 23, 211-215.	1.1	18
363	Letter to the Editor. Lupus, 2001, 10, 897-898.	0.8	18
364	Endothelium activation in the anti-phospholipid syndrome. Biomedicine and Pharmacotherapy, 2003, 57, 282-286.	2.5	18
365	Systemic lupus erythematosus and the SLE galaxy. Autoimmunity Reviews, 2010, 10, 1-2.	2.5	18
366	Development of a Certified Reference Material for myeloperoxidase-anti-neutrophil cytoplasmic autoantibodies (MPO-ANCA). Clinica Chimica Acta, 2017, 467, 48-50.	0.5	18
367	Anti-atherogenic Modification of Serum Lipoprotein Function in Patients with Rheumatoid Arthritis after Tocilizumab Treatment, a Pilot Study. Journal of Clinical Medicine, 2020, 9, 2157.	1.0	18
368	Kallikreins and lupus nephritis. Journal of Clinical Investigation, 2009, 119, 768-771.	3.9	18
369	Successful sequential therapy with rituximab and belimumab in patients with active systemic lupus erythematosus: a case series. Clinical and Experimental Rheumatology, 2018, 36, 643-647.	0.4	18
370	Response to tetanus vaccination in infants exposed in utero to immunosuppressants for maternal autoimmune disorders. Lupus, 2007, 16, 129-132.	0.8	17
371	Aspirin in asymptomatic patients with confirmed positivity of antiphospholipid antibodies? Yes (in some) Tj ETQq1 1 0.784314 rgBT /Ov	1.0	17
372	IRF5 is associated with primary antiphospholipid syndrome, but is not a major risk factor. Arthritis and Rheumatism, 2010, 62, 1201-1202.	6.7	17
373	Preliminary evaluation of the first international reference preparation for anticitrullinated peptide antibodies. Annals of the Rheumatic Diseases, 2012, 71, 1388-1392.	0.5	17
374	Low Preconception Complement Levels Are Associated with Adverse Pregnancy Outcomes in a Multicenter Study of 260 Pregnancies in 197 Women with Antiphospholipid Syndrome or Carriers of Antiphospholipid Antibodies. Biomedicines, 2021, 9, 671.	1.4	17
375	Invitro and exvivo effect of RU41740 on human polymorphonuclear leukocyte function. International Journal of Immunopharmacology, 1988, 10, 121-133.	1.1	16
376	In vivo immunopotentiating activity of thymopentin in aging humans: Modulation of IL-2 receptor expression. Clinical Immunology and Immunopathology, 1988, 48, 140-149.	2.1	16
377	Immunomodulation of murine experimental SLE-like disease by interferon-Î³. Lupus, 1998, 7, 445-454.	0.8	16
378	Impaired bradykinin response to ischaemia and exercise in patients with mild congestive heart failure during angiotensin-converting enzyme treatment. Relationships with endothelial function, coagulation and inflammation. British Journal of Haematology, 2005, 130, 113-120.	1.2	16

#	Article	IF	Citations
379	Power Doppler Sonography and Clinical Monitoring for Hyaluronic Acid Treatment of Rhizarthrosis: A Pilot Study. Journal of Hand and Microsurgery, 2016, 03, 51-54.	0.1	16
380	Inflammatory Joint Disorders and Neutrophilic Dermatoses: a Comprehensive Review. Clinical Reviews in Allergy and Immunology, 2018, 54, 269-281.	2.9	16
381	A WHO Reference Reagent for lupus (anti-dsDNA) antibodies: international collaborative study to evaluate a candidate preparation. Annals of the Rheumatic Diseases, 2019, 78, 1677-1680.	0.5	16
382	Pitfalls of antinuclear antibody detection in systemic lupus erythematosus: the positive experience of a national multicentre study. Annals of the Rheumatic Diseases, 2019, 78, e50-e50.	0.5	16
383	Complement Activation and Thrombin Generation by MBL Bound to Î²2-Glycoprotein I. Journal of Immunology, 2020, 205, 1385-1392.	0.4	16
384	Integrative epigenomics in SjÃ¶grenÂ´s syndrome reveals novel pathways and a strong interaction between the HLA, autoantibodies and the interferon signature. Scientific Reports, 2021, 11, 23292.	1.6	16
385	Prothrombotic biomarkers in patients with rheumatoid arthritis: the beneficial effect of IL-6 receptor blockade. Clinical and Experimental Rheumatology, 2016, 34, 451-8.	0.4	16
386	Effects of chronic heroin addiction on pituitary-thyroid function in man. Journal of Endocrinological Investigation, 1980, 3, 251-255.	1.8	15
387	Antiphospholipid Antibodies and Endothelial Cells. Lupus, 1994, 3, 267-269.	0.8	15
388	Pentraxin 3, a novel cardiovascular biomarker, is expressed in aortic specimens of patients with coronary artery disease with and without rheumatoid arthritis. Cardiovascular Pathology, 2013, 22, 324-331.	0.7	15
389	What is known about pediatric antiphospholipid syndrome?. Expert Review of Hematology, 2016, 9, 977-985.	1.0	15
390	Antiphospholipid autoantibody detection is important in all patients with systemic autoimmune diseases. Journal of Autoimmunity, 2020, 115, 102524.	3.0	15
391	An elevated polyclonal free light chain level reflects a strong interferon signature in patients with systemic autoimmune diseases. Journal of Translational Autoimmunity, 2021, 4, 100090.	2.0	15
392	A New Case of IgE Myeloma. Acta Haematologica, 1991, 85, 41-44.	0.7	14
393	Î²-Endorphin content in HIV-infected HuT78 cell line and in peripheral lymphocytes from HIV-positive subjects. Peptides, 1994, 15, 769-775.	1.2	14
394	In vitro inhibition of enterobacteria-reactive CD4+CD25â˜ T cells and suppression of immunoinflammatory colitis in mice by the novel immunomodulatory agent VGX-1027. European Journal of Pharmacology, 2008, 586, 313-321.	1.7	14
395	Usefulness of cardiovascular biomarkers and cardiac imaging in systemic rheumatic diseases. Autoimmunity Reviews, 2010, 9, 845-848.	2.5	14
396	Limited cutaneous systemic sclerosis skin demonstrates distinct molecular subsets separated by a cardiovascular development gene expression signature. Arthritis Research and Therapy, 2017, 19, 156.	1.6	14

#	Article	IF	Citations
397	Standardization of autoimmune testing â€“ is it feasible?. Clinical Chemistry and Laboratory Medicine, 2018, 56, 1734-1742.	1.4	14
398	Patients with a history of stable or unstable coronary heart disease have different acute phase responses to an inflammatory stimulus. Atherosclerosis, 2008, 196, 835-840.	0.4	13
399	The development of a simple questionnaire to screen patients with SLE for the presence of neuropsychiatric symptoms in routine clinical practice. Lupus, 2011, 20, 485-492.	0.8	13
400	Autoantibodies in Systemic Autoimmune Disorders. Journal of Immunology Research, 2014, 2014, 1-2.	0.9	13
401	International standards for IgG and IgM anti-Î²2glycoprotein antibody measurement. Lupus, 2014, 23, 1317-1319.	0.8	13
402	Autoantibody profiling in APS. Lupus, 2014, 23, 1262-1264.	0.8	13
403	Uniphasic Blanching of the Fingers, Abnormal Capillaroscopy in Nonsymptomatic Digits, and Autoantibodies: Expanding Options to Increase the Level of Suspicion of Connective Tissue Diseases beyond the Classification of Raynaudâ€™s Phenomenon. Journal of Immunology Research, 2015, 2015, 1-7.	0.9	13
404	A comparison between nailfold capillaroscopy patterns in adulthood in juvenile and adult-onset systemic sclerosis: A EUSTAR exploratory study. Microvascular Research, 2015, 102, 19-24.	1.1	13
405	Effectiveness and Tolerability of Repeated Courses of Viscosupplementation in Symptomatic Hip Osteoarthritis: A Retrospective Observational Cohort Study of High Molecular Weight vs. Medium Molecular Weight Hyaluronic Acid vs. No Viscosupplementation. Frontiers in Pharmacology, 2019, 10, 1007.	1.6	13
406	Personalized medicine in rheumatoid arthritis: How immunogenicity impacts use of TNF inhibitors. Autoimmunity Reviews, 2020, 19, 102509.	2.5	13
407	Antiâ€phospholipid antibodies and reproductive failures. American Journal of Reproductive Immunology, 2021, 85, e13258.	1.2	13
408	Antibodies to cardiac Purkinje cells: Further characterization in autoimmune diseases and atrioventricular heart block. Clinical Immunology and Immunopathology, 1987, 42, 141-150.	2.1	12
409	Introduction. Autoimmunity Reviews, 2011, 10, 239-240.	2.5	12
410	Obstetric Antiphospholipid Syndrome: Lobsters Only? Or Should We Also Look for Selected Red Herrings?. Journal of Rheumatology, 2015, 42, 158-160.	1.0	12
411	Antiphospholipid antibodies and COVID-19 thrombotic vasculopathy: one swallow does not make a summer. Annals of the Rheumatic Diseases, 2021, 80, 1105-1107.	0.5	12
412	Potential Effect of Anti-Inflammatory Treatment on Reducing the Cardiovascular Risk in Rheumatoid Arthritis. Current Vascular Pharmacology, 2012, 10, 639-646.	0.8	12
413	Anti-Ro/SSA-p200 antibodies in the prediction of congenital heart block. An Italian multicentre cross-sectional study on behalf of the 'Forum Interdisciplinare per la Ricerca nelle Malattie Autoimmuni (FIRMA) Group'. Clinical and Experimental Rheumatology, 2014, 32, 848-54.	0.4	12
414	FK-506 prevents diabetes in diabetes-prone BB/Wor rats. International Journal of Immunopharmacology, 1991, 13, 1027-1030.	1.1	11

#	Article	IF	Citations
415	Hand impairment in systemic sclerosis: association of different hand indices with organ involvement. Scandinavian Journal of Rheumatology, 2010, 39, 393-397.	0.6	11
416	The role of biologic agents in damage progression in rheumatoid arthritis: indirect comparison of data coming from randomized clinical trials. Therapeutic Advances in Musculoskeletal Disease, 2012, 4, 213-223.	1.2	11
417	Is there a need for new thresholds to define remission and low disease activity by Disease Activity Score 28 calculated with C reactive protein? Real life data from a local registry. Annals of the Rheumatic Diseases, 2015, 74, e5-e5.	0.5	11
418	Clinical, Ultrasound, and Predictability Outcomes Following Certolizumab Pegol Treatment (with) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 6 CZP-SPEED Study. Advances in Therapy, 2018, 35, 1153-1168.	1.3	11
419	Editorial: Systemic Lupus Erythematosus and Antiphospholipid Syndrome. Frontiers in Immunology, 2019, 10, 199.	2.2	11
420	The IMMENSE Study: The Interplay Between iMMune and ENdothelial Cells in Mediating Cardiovascular Risk in Systemic Lupus Erythematosus. Frontiers in Immunology, 2020, 11, 572876.	2.2	11
421	IgM antibodies against malondialdehyde and phosphorylcholine in different systemic rheumatic diseases. Scientific Reports, 2020, 10, 11010.	1.6	11
422	Endothelial Cell Autoantibodies. , 1996, , 245-252.		11
423	Anti-Phospholipid Antibodies and Coronavirus Disease 2019: Vaccination Does Not Trigger Early Autoantibody Production in Healthcare Workers. Frontiers in Immunology, 0, 13, .	2.2	11
424	Histopathological findings in a case of systemic lupus erythematosus-associated anti-phospholipid syndrome. Clinical Rheumatology, 1991, 10, 211-214.	1.0	10
425	Protection from Experimental Autoimmune Thyroiditis in CBA Mice with the Novel Immunosuppressant Deoxyspergualin. Scandinavian Journal of Immunology, 1994, 39, 333-336.	1.3	10
426	Pathogenic mechanisms of antiphospholipid syndrome: a new autoimmune disease. Drug Discovery Today Disease Mechanisms, 2004, 1, 309-314.	0.8	10
427	Lung Disease in Antiphospholipid Syndrome. Seminars in Respiratory and Critical Care Medicine, 2019, 40, 278-294.	0.8	10
428	Prevention of Spontaneous Autoimmune Diabetes in Diabetes-Prone BB Rats by Prophylactic Treatment with Antirat Interferon-Â Antibody. Endocrinology, 1997, 138, 281-288.	1.4	10
429	Immunopharmacological activity of cefodizime in young and elderly subjects: In vitro and ex vivo studies. Infection, 1992, 20, S61-S63.	2.3	9
430	N-TproBNP as Biomarker in Systemic Sclerosis. Clinical Reviews in Allergy and Immunology, 2012, 43, 292-301.	2.9	9
431	Less Travelled Roads in Clinical Immunology and Allergy: Drug Reactions and the Environmental Influence. Clinical Reviews in Allergy and Immunology, 2013, 45, 1-5.	2.9	9
432	Cerebrospinal fluid phosphorylated neurofilament heavy chain and chitotriosidase in primary lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 221-223.	0.9	9

#	Article	IF	Citations
433	Association of subcutaneous belimumab and long-term antimalarial treatment reduces antiphospholipid antibodies levels in systemic lupus erythematosus: post-hoc analysis of a randomised placebo-controlled trialâ€"comment on: â€˜Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosusâ€™ by Chatzidionysiou et al.. Annals of the Rheumatic Diseases, 2022, 81, e140-e140.	0.5	9
434	Feasibility, acceptability and construct validity of EQ-5D in systemic sclerosis. Swiss Medical Weekly, 2016, 146, w14394.	0.8	9
435	Detection and Further Characterization of a Newly Described Microsomal Autoantibody Associated with Chronic Delta Infection. Digestion, 1986, 33, 181-188.	1.2	8
436	Gastric Histology and Function Tests in Italian Patients with Dermatitis Herpetiformis. Scandinavian Journal of Gastroenterology, 1990, 25, 357-362.	0.6	8
437	Antiphospholipid antibodies and endothelial cells: an unending story. Lupus, 1995, 4, 169-171.	0.8	8
438	Prevention by rolipram of concanavalin A-induced T-cell-dependent hepatitis in mice. European Journal of Pharmacology, 1999, 367, 399-404.	1.7	8
439	Modulation of adhesion molecule expression on endothelial cells: to be or not to be?. Journal of Thrombosis and Haemostasis, 2003, 1, 2280-2282.	1.9	8
440	Effects of the immunomodulator, VGXâ€1027, in endotoxinâ€induced uveitis in Lewis rats. British Journal of Pharmacology, 2008, 155, 722-730.	2.7	8
441	Anti-GalNAcÎ²: A novel anti-glycan autoantibody associated with pregnancy loss in women with antiphospholipid syndrome and in a mouse experimental model. Journal of Autoimmunity, 2012, 39, 420-427.	3.0	8
442	The comparison of effects of biologic agents on rheumatoid arthritis damage progression is biased by period of enrolment: Data from a systematic review and meta-analysis. Seminars in Arthritis and Rheumatism, 2014, 43, 730-737.	1.6	8
443	Oxidation of Î²2-glycoprotein I associates with IgG antibodies to domain I in patients with antiphospholipid syndrome. PLoS ONE, 2017, 12, e0186513.	1.1	8
444	Thrombosis and Anti-phospholipid Syndrome: a 5-Year Update on Treatment. Current Rheumatology Reports, 2018, 20, 44.	2.1	8
445	Antiendothelial Cell Antibodies (AECA): From a Laboratory Curiosity to Another Useful Autoantibody. , 1999, , 285-294.		8
446	The Effects of Thymopentin on the Development of SLE-Like Syndrome in the MRL/lpr-lpr Mouse. Scandinavian Journal of Immunology, 1994, 40, 549-556.	1.3	7
447	Measurement of Electrical Skin Impedance of Dermal-Visceral Zones as a Diagnostic Tool for Disorders of the Immune System. Lupus, 2006, 15, 457-461.	0.8	7
448	Pathophysiology of the antiphospholipid syndrome (APS). Revue De Medecine Interne, 2012, 33, A2-A4.	0.6	7
449	Detection of anti-adalimumab antibodies in a RA responsive cohort of patients using three different techniques. Analytical Biochemistry, 2019, 566, 133-138.	1.1	7
450	Production of anti-PF4 antibodies in antiphospholipid antibody-positive patients is not affected by COVID-19 vaccination. RMD Open, 2022, 8, e001902.	1.8	7

#	Article	IF	Citations
451	Reliability and validity of the Italian version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument in patients with systemic sclerosis. Clinical and Experimental Rheumatology, 2015, 33, S55-60.	0.4	7
452	Increased Rate of Survival in Streptococcus pneumoniae-Infected Rats Treated with the New Immunomodulator Pidotimod. Scandinavian Journal of Infectious Diseases, 1992, 24, 821-823.	1.5	6
453	Anti-neutrophil Cytoplasmic Antibody-Enriched IgG Induces Adhesion of Human T Lymphocytes to Extracellular Matrix Proteins. Clinical Immunology and Immunopathology, 1997, 83, 245-253.	2.1	6
454	Should our approach to the anticardiolipin assay change 20â€ƒyears after its discovery?. Journal of Thrombosis and Haemostasis, 2004, 2, 1074-1076.	1.9	6
455	The immunobiology of apotransferrin in type 1 diabetes. Clinical and Experimental Immunology, 2012, 169, 244-252.	1.1	6
456	The challenging definition of naÃ¯ve patient for biological drug use. Autoimmunity Reviews, 2015, 14, 543-546.	2.5	6
457	First steps in the standardization of immunoglobulin IgG myeloperoxidaseâ€antiâ€neutrophil cytoplasmic antibody measurements. Clinical and Experimental Immunology, 2016, 183, 193-205.	1.1	6
458	Certified reference material against PR3 ANCA IgG autoantibodies. From development to certification. Clinical Chemistry and Laboratory Medicine, 2019, 57, 1197-1206.	1.4	6
459	Effects of Antibody Responses to Pre-Existing Coronaviruses on Disease Severity and Complement Activation in COVID-19 Patients. Microorganisms, 2022, 10, 1191.	1.6	6
460	Antiendothelial Cell Antibodies in Primary Vasculitides. Contributions To Nephrology, 1991, 94, 89-97.	1.1	5
461	Immunosuppressive activity of 15-deoxyspergualin on normal and autoimmune peripheral blood mononuclear cells. European Journal of Pharmacology, 1996, 311, 213-220.	1.7	5
462	Pathogenetic associations of maternal Anti-Ro/SSA antibodies. Lupus, 2002, 11, 650-650.	0.8	5
463	Short-term prophylaxis with deoxyspergualin prevents testicular autoimmunity in mice. European Journal of Pharmacology, 2002, 450, 209-212.	1.7	5
464	Prevalence of autoantibodies against structure specific recognition protein 1 in systemic lupus erythematosus. Lupus, 2004, 13, 463-468.	0.8	5
465	Neonatal lupus and a seronegative mother. Lancet, The, 2004, 363, 1038.	6.3	5
466	European Forum on Antiphospholipid Antibodies: research in progress. Lupus, 2009, 18, 924-929.	0.8	5
467	Pre-conceptional exposure to rituximab: comment on the article by Ojeda-Uribe et al.. Clinical Rheumatology, 2013, 32, 727-728.	1.0	5
468	The kaleidoscopic manifestations of systemic vasculitis. Autoimmunity Reviews, 2013, 12, 459-462.	2.5	5

#	Article	IF	Citations
469	Consumption of complement in a 26-year-old woman with severe thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. Journal of Autoimmunity, 2021, 124, 102728.	3.0	5
470	Development of a certified reference material for anti-Î²2-glycoprotein I IgGÂâ€“ commutability studies. Clinical Chemistry and Laboratory Medicine, 2021, 59, 325-332.	1.4	5
471	Vitamin D and Anti-Phospholipid Antibody Syndrome: A Comprehensive Review. Open Rheumatology Journal, 2018, 12, 248-260.	0.1	5
472	Enrichment of IgG anti-DNA-producing lymphoblastoid cell lines by antigen-coated immunomagnetic beads. Clinical Immunology and Immunopathology, 1992, 65, 39-44.	2.1	4
473	ANTI-ENDOTHELIAL CELL AUTOANTIBODIES. , 2007, , 725-731.		4
474	Chapter 4 Mechanisms of Action of Antiphospholipid Antibodies. Handbook of Systemic Autoimmune Diseases, 2009, 10, 55-67.	0.1	4
475	Antinuclear Antibody Test: When to Order?. American Journal of Medicine, 2013, 126, e17.	0.6	4
476	Sparing effect of hemiplegia on skin fibrosis and microvascular involvement: Reports of two cases of systemic sclerosis and review of the literature. Seminars in Arthritis and Rheumatism, 2015, 44, 597-601.	1.6	4
477	Change Over Time in the Pattern of Clinical Response to First-line Biologic Drugs in Patients with Rheumatoid Arthritis: Observational Data in a Real-life Setting. Journal of Rheumatology, 2017, 44, 262-263.	1.0	4
478	The incidence of cardiovascular events in Italian patients with systemic lupus erythematosus is lower than in North European and American cohorts. Medicine (United States), 2018, 97, e0370.	0.4	4
479	Immunological Abnormalities in the Antiphospholipid Syndrome. , 2002, , 271-283.		3
480	Mechanisms of Antiphospholipid Antibody-Mediated Pregnancy Morbidity. , 2017, , 117-143.		3
481	Therapy for antiphospholipid miscarriages: Throwing the baby out with the bathwater?. American Journal of Reproductive Immunology, 2018, 79, e12792.	1.2	3
482	Correspondence on â€œEuropean League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performanceâ€• Annals of the Rheumatic Diseases, 2023, 82, e193-e193.	0.5	3
483	Clinical and Prognostic Significance of Non-criteria Antiphospholipid Antibody Tests. , 2017, , 171-187.		3
484	Autoantibody pattern in non-A, non-B hepatitis. Infection, 1984, 12, 91-95.	2.3	2
485	Efficacy of prednisone to induce remission in recent onset type I (insulin dependent) diabetic patients. Klinische Wochenschrift, 1987, 65, 244-244.	0.6	2
486	Failure of Exogenously Administered Interferon-Î³ or Blockage of Endogenous Interleukin-4 with Specific Inhibitors to Augment the Incidence of Autoimmune Diabetes in Male NOD Mice. Autoimmunity, 1999, 30, 71-80.	1.2	2

#	Article	IF	Citations
487	Neonatal lupus syndromes. APLAR Journal of Rheumatology, 2004, 7, 285-291.	0.2	2
488	Anti-t-PA antibodies in acute myocardial infarction after thrombolysis with rt-PA. European Journal of Internal Medicine, 2010, 21, 25-29.	1.0	2
489	Comparative Analysis of Different Specific Indices of Hand Impairment in Systemic Sclerosis. Journal of Rheumatology, 2010, 37, 2192-2193.	1.0	2
490	Long-term Outcome of Children Born to Women with Autoimmune Rheumatic Diseases: A Multicentre, Nationwide Study on 299 Randomly Selected Individuals. Clinical Reviews in Allergy and Immunology, 2022, 62, 346-353.	2.9	2
491	Microarray evaluation of allergen-specific IgE in eosinophilic granulomatosis with polyangiitis. Annals of the Rheumatic Diseases, 2021, 80, 1247-1248.	0.5	2
492	Value of digital biomarkers in precision medicine: implications in cancer, autoimmune diseases, and COVID-19. Expert Review of Precision Medicine and Drug Development, 2021, 6, 235-238.	0.4	2
493	Functional Heterogeneity of Pathogenic Anti-Endothelial Cell Antibodies. , 2001, , 211-220.		2
494	Serum chemerin in systemic sclerosis: a novel marker of early diffuse disease?. Clinical and Experimental Rheumatology, 2017, 35 Suppl 106, 223-224.	0.4	2
495	In vitro and ex vivo effect of tiaprofenic acid on human peripheral blood mononuclear cells. International Journal of Immunopharmacology, 1992, 14, 1279-1284.	1.1	1
496	Deoxyspergualin neither counteracts lipopolysaccharide (LPS) or Staphylococcus aureus enterotoxin-B (SEB) induced lethality in mice nor does it modulate the release of tumor necrosis factor-Î±. Immunology Letters, 1998, 61, 63-66.	1.1	1
497	Î²-Endorphin Concentrations Are Decreased in Peripheral Blood Mononuclear Cells of Chronic Fatigue Syndrome Patients: Comparison with Depression. Journal of Musculoskeletal Pain, 1999, 7, 303-307.	0.3	1
498	Prevention and Treatment of Lethal Murine Endotoxemia by the Novel Immunomodulatory Agent MFP-14. Antimicrobial Agents and Chemotherapy, 2001, 45, 1591-1594.	1.4	1
499	Non-organ Specific Autoimmunity Involvement in Cardiovascular Disease. Handbook of Systemic Autoimmune Diseases, 2003, 1, 41-51.	0.1	1
500	Statins and autoimmune diseases. APLAR Journal of Rheumatology, 2004, 7, 278-284.	0.2	1
501	Autoantibodies and Skin Involvement in Systemic Autoimmune Diseases. Handbook of Systemic Autoimmune Diseases, 2006, , 29-36.	0.1	1
502	Update on Pregnancy in Autoimmune Diseases. Women's Health, 2007, 3, 417-420.	0.7	1
503	Update on antiphospholipid antibodies: clinical significance. International Journal of Clinical Rheumatology, 2009, 4, 551-560.	0.3	1
504	The Role of Ultrasonography in the Assessment of Skeletal Hand Involvement in Systemic Sclerosis. Journal of Medical Ultrasound, 2011, 19, 141-142.	0.2	1

#	Article	IF	Citations
505	Rheumatoid Factors. , 2014, , 751-760.		1
506	Autoantibodies â€“ Future Trends. , 2014, , 825-828.		1
507	Mechanisms of Action of the Antiphospholipid Antibodies. Handbook of Systemic Autoimmune Diseases, 2017, 12, 31-46.	0.1	1
508	Immediate treatment with tumour necrosis factor inhibitors in synthetic disease-modifying anti-rheumatic drugs-naÃ¯ve patients with rheumatoid arthritis: results of a modified Italian Expert Consensus. Rheumatology, 2018, 57, vii32-vii41.	0.9	1
509	O31â€...Integrative analysis reveals a molecular stratification of systemic autoimmune diseases. , 2020, , .		1
510	Antibodies and diagnostic tests in antiphosholipid syndrome. , 2021, , 565-574.		1
511	Antiphospholipid/Endothelial Cell Interaction in the Pathogenesis of the Antiphospholipid Syndrome. , 2002, , 79-89.		1
512	Accelerated Atherosclerosis in Autoimmune Diseases. , 2008, , 383-387.		1
513	What is the Mechanism(s) of Antiphospholipid Antibody-Mediated Pregnancy Morbidity?. , 2012, , 79-101.		1
514	Myocardial involvement in anti-phospholipid syndrome: Beyond acute myocardial infarction. Autoimmunity Reviews, 2022, 21, 102990.	2.5	1
515	Introduction. Clinical Reviews in Allergy and Immunology, 1997, 15, 1-3.	2.9	0
516	The Story of the Murine Antiendothelial Monoclonal Antibody BGM : From Patients' Bedside to Laboratory Bench and From Animal Models to Patients. Clinical Reviews in Allergy and Immunology, 2000, 18, 3-10.	2.9	0
517	Antiendothelial cell antibodies in vascular inflammation. Clinical and Applied Immunology Reviews, 2001, 1, 135-146.	0.4	0
518	Are Cardiovascular Diseases a Subspeciality of Clinical Immunology?. Clinical Reviews in Allergy and Immunology, 2002, 23, 243-246.	2.9	0
519	Offspring of Women with Systemic Autoimmune Diseases: Fetal and Neonatal Complications and Inheritance of Autoimmune Diseases. Handbook of Systemic Autoimmune Diseases, 2005, 4, 111-121.	0.1	0
520	RHEUMATOID FACTORS. , 2007, , 755-762.		0
521	Fetal and Obstetric Manifestations in the Antiphospholipid Syndrome. Current Rheumatology Reviews, 2010, 6, 18-24.	0.4	0
522	What is the Genetics of Antiphospholipid Antibodies/Syndrome?. , 2012, , 41-56.		0

#	Article	IF	Citations
523	Immunotherapeutic Agents for SLE. , 2012, , .		0
524	Regulation of auto-antibody production by persisting auto-immune complexes on follicular dendritic cells. Annals of the Rheumatic Diseases, 2012, 71, A38.1-A38.	0.5	0
525	A5.5â€...Antibodies against Domain I of Î²2 Glycoprotein I in Antiphospholipid Antibody Syndrome. Annals of the Rheumatic Diseases, 2013, 72, A31.3-A32.	0.5	0
526	Antiendothelial Cell Antibodies. , 2014, , 723-729.		0
527	Cardiovascular Issues in SLE. Rare Diseases of the Immune System, 2016, , 133-145.	0.1	0
528	05.09â€...The role of the european consensus finding study group (ecfsg) in characterising new tentative reference standards for autoantibody measurement. , 2017, , .		0
529	Hormones and Autoimmunity. , 2019, , 181-190.		0
530	Personalized Medicine in Autoimmunity. , 2019, , 619-624.		0
531	FRI0186â€...HYDROXYCHLOROQUINE ON THE TOP OF STANDARD TREATMENT WITH LOW DOSE ASPIRIN AND LOW MOLECULAR WEIGHT HEPARIN SIGNIFICANTLY REDUCES THE PROBABILITY OF PREGNANCY MORBIDITY IN WOMEN WITH MULTIPLE POSITIVITY FOR ANTI-PHOSPHOLIPID ANTIBODIES. , 2019, , .		0
532	AB0201â€...THE PATHOGENIC EFFECTS OF IMMUNE COMPLEXES CONTAINING SCLERODERMA-SPECIFIC AUTOANTIBODIES IN ENDOTHELIAL CELLS. , 2019, , .		0
533	FRI0569â€...WHAT DOES IT MEAN TO BECOME PREGNANT WITH JUVENILE IDIOPATHIC ARTHRITIS? A MONOCENTRIC EXPERIENCE IN A TERTIARY CENTRE OF MILAN DEDICATED TO YOUNG ADULTS AFFECTED BY JIA. , 2019, , .		0
534	FRI0185â€...HYDROXYCHLOROQUINE FOR THE PREVENTION OF RELAPSES IN A SERIES OF 812 PATIENTS WITH PRIMARY ANTIPHOSPHOLIPID SYNDROME: THE HIBISCUS RETROSPECTIVE STUDY. , 2019, , .		0
535	The Geoepidemiology of Autoimmune Liver Disease. , 2014, , 27-43.		0
536	Immunopotentiating Activity of Thymopentin Treatment in Elderly Subjects. , 1990, , 537-550.		0
537	Antibodies and Diagnostic Tests in Antiphospholipid Syndrome. , 2016, , 495-501.		0
538	Immunologic Abnormalities in the Antiphospholipid Syndrome. , 2018, , 235-247.		0
539	IFI16 and Anti-IFI16 as Novel Biomarkers for Sjoegrenâ€™s Syndrome: Preliminary Data. Proceedings (mdpi), 2019, 35, .	0.2	0
540	Role of anti-Î²2 glycoprotein I antibodies in antiphospholipid syndromeglycoprotein I antibodies in antiphospholipid syndrome. Clinical Reviews in Allergy and Immunology, 2007, 32, 67-73.	2.9	0

#	Article	IF	Citations
541	Reply to: Vaccination for hepatitis B virus in an Australian pre-biologic population with rheumatoid arthritis. Clinical and Experimental Rheumatology, 2019, 37, 164.	0.4	0